Gaudium IVF (GAUDIUMIVF)

FairStock Score: 55/100 — STEADY

Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 56.20% and profit growth of 53.69% show strong momentum and operating leverage.
• ROCE of 48.63% indicates highly capital-efficient deployment of capital.
• Piotroski F-Score of 7/9 suggests solid financial health and earnings quality.
• Promoter holding of 71.29% aligns management interest with outside shareholders.
• PEG ratio of 0.45 points to reasonable valuation relative to its high growth rate.

Concerns

• P/B of 16.72 against book value of ₹7.54 means investors are paying a huge premium for intangible assets and future growth.
• ROE is not available, making it difficult to assess return on shareholders' equity directly.
• No dividend yield, so investors receive no cash return while waiting for growth to play out.
• Debt/Equity is N/A, leaving the leverage profile unclear.

AI Analysis

Gaudium IVF is a high-growth healthcare service provider. At first glance, the numbers show exactly the kind of compounding compounder I look for: sales up 56.20% and profit up 53.69%, with a latest quarter of ₹50 Cr revenue and ₹13 Cr profit. ROCE at 48.63% is extraordinary – it suggests the business is deploying capital very efficiently. The Piotroski score of 7/9 reinforces that the reported earnings quality is solid, not merely paper profits. While I dislike not having ROE, the return on capital employed and growth numbers provide enough evidence of an underlying franchise. My concern is price and certainty. At ₹126.09, the market capitalisation is ₹584 Cr, a P/E of 24.86 and a P/B of 16.72 against book value of just ₹7.54. For a business growing at over 50%, a PEG of 0.45 appears reasonable, and I can stomach a higher multiple if returns remain high and growth persists. Yet a book value of ₹7.54 means investors are paying a huge premium for intangible assets and future growth. There is also no dividend yield; management is reinvesting everything, which is fine for a fast grower but leaves no margin of safety from cash returns. I would not call this a Graham-style asset play. This is a fast-growing equity whose value depends on continuing to deliver 50%-plus growth. The promoter holding of 71.29% aligns interests, but it also reduces floating stock, which can exaggerate both ups and downs. The 52-week range of ₹69.18 to ₹163.70 shows this stock can move violently. I would want to see several more quarters of execution and a lower entry price, or maintained growth, before treating it as a core Buffett-style holding.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer